- Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
- Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
- Agile Therapeutics Announces Delisting from Nasdaq
- Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
- Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
- Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
- Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
- Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
- The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
More ▼
Key statistics
On Wednesday, Agile Therapeutics Inc (AGRX:QBB) closed at 1.41, 605.00% above the 52 week low of 0.20 set on Mar 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.41 |
---|---|
High | 1.42 |
Low | 1.41 |
Bid | -- |
Offer | -- |
Previous close | 1.41 |
Average volume | 621.56k |
---|---|
Shares outstanding | 6.86m |
Free float | 6.84m |
P/E (TTM) | -- |
Market cap | 9.67m USD |
EPS (TTM) | -3.65 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 17:47 BST.
More ▼